Beijing SL Pharmaceutical Co Ltd banner
B

Beijing SL Pharmaceutical Co Ltd
SZSE:002038

Watchlist Manager
Beijing SL Pharmaceutical Co Ltd
SZSE:002038
Watchlist
Price: 6.87 CNY -1.15% Market Closed
Market Cap: ¥7.1B

Beijing SL Pharmaceutical Co Ltd
Accrued Liabilities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Beijing SL Pharmaceutical Co Ltd
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
B
Beijing SL Pharmaceutical Co Ltd
SZSE:002038
Accrued Liabilities
¥36.6m
CAGR 3-Years
16%
CAGR 5-Years
20%
CAGR 10-Years
21%
Beigene Ltd
HKEX:6160
Accrued Liabilities
¥4.9B
CAGR 3-Years
43%
CAGR 5-Years
45%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
RemeGen Co Ltd
SSE:688331
Accrued Liabilities
¥327.2m
CAGR 3-Years
33%
CAGR 5-Years
41%
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
Accrued Liabilities
¥137.5m
CAGR 3-Years
15%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Beijing SL Pharmaceutical Co Ltd
Glance View

Market Cap
7.1B CNY
Industry
Biotechnology

Beijing SL Pharmaceutical Co Ltd. is a notable player in the pharmaceutical sector, navigating the rigorous demands of healthcare with a focus on innovation and market responsiveness. Born from a deep understanding of the medical field, the company has carved a niche by focusing on the development, manufacturing, and marketing of a broad spectrum of pharmaceutical products. Among its specialties, Beijing SL Pharmaceutical is renowned for its expertise in producing complex chemicals and biologics, which are vital in treating various medical conditions ranging from cardiovascular diseases to neurological disorders. The company puts significant emphasis on research and development, ensuring that its product pipeline remains robust and poised for future growth. The commercial success of Beijing SL Pharmaceutical is largely driven by its keen adaptation to the dynamic healthcare needs both domestically and internationally. The company leverages its extensive distribution network and strategic partnerships with healthcare providers and institutions to ensure that its products reach patients efficiently. By maintaining a diverse product portfolio that caters to pressing medical needs, the company combines patient-centric strategies with astute business acumen to maintain steady revenue streams. Furthermore, its commitment to quality and safety standards reinforces trust among stakeholders, thereby enabling Beijing SL Pharmaceutical to thrive in a competitive landscape. As it continues to expand, the company remains vigilant in enhancing its technological capabilities and market reach, always with an eye on delivering value through health and wellness.

Intrinsic Value
4.41 CNY
Overvaluation 36%
Intrinsic Value
Price ¥6.87
B

See Also

What is Beijing SL Pharmaceutical Co Ltd's Accrued Liabilities?
Accrued Liabilities
36.6m CNY

Based on the financial report for Sep 30, 2025, Beijing SL Pharmaceutical Co Ltd's Accrued Liabilities amounts to 36.6m CNY.

What is Beijing SL Pharmaceutical Co Ltd's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
21%

Over the last year, the Accrued Liabilities growth was 12%. The average annual Accrued Liabilities growth rates for Beijing SL Pharmaceutical Co Ltd have been 16% over the past three years , 20% over the past five years , and 21% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett